Printer Friendly

Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars.

SHANGHAI, China, May 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech , a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, is proud to announce that the distinguished Stanford University Professor Barry M. Trost ( http://www.stanford.edu/group/bmtrost/ ) has visited WuXi PharmaTech and given two seminars on May 19 and 20.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Barry M. Trost, Tamaki Professor of Humanities and Sciences in the chemistry department at Stanford University, is a world renowned organic chemist and a fellow of the U.S. National Academy of Sciences. Professor Barry M. Trost's professional interests include asymmetric allylic alkylation and efficient enantioselective synthesis. He has made great contributions to the modern synthetic organic chemistry and green chemistry. Many widely used chemistry reactions, such as the Trost asymmetric allylic alkylation, Tsuji-Trost reaction and the Trost ligand, are named after him.

Professor Trost studied at the University of Pennsylvania and received his Ph.D. from the Massachusetts Institute of Technology in 1965. He was a professor at the University of Wisconsin-Madison from 1965 until his appointment to Stanford University in 1987. Professor Trost has more than 820 scientific publications, over 320 lectures at various national and international meetings, and over 40 worldwide awards and honors.

As another luminary speaker of WuXi PharmaTech Science Seminar Series, Professor Trost gave the WuXi scientists two lectures titled "New Synthetic Strategies to Bioactive Products" and "On Inventing Reactions for Atom Economy." Professor Trost captivated the audience from beginning to end during the lectures and answered questions from the packed crowd.

"This is my first time to give a lecture to a pharmaceutical service company in China. I am very impressed by WuXi's Science Seminar Series program as well as the research capability and scientific acumen of WuXi's young scientists. Talents are absolutely the key to success for any business, especially for WuXi which provides high quality research and development services to global life science companies," commented Professor Barry M. Trost.

"We are very privileged to have Dr. Trost share his brilliant expertise with our young scientists," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "As we broaden our R&D service scope our success very much depends on the quality of our scientists. Investing in people is and will continue to be one of our top strategies."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com/ .
 For more information, please contact:

 Sherry Shao
 Tel: +86-21-5046-4002
 Email: pr@pharmatechs.com



CONTACT: Sherry Shao of WuXi PharmaTech, +86-21-5046-4002, or pr@pharmatechs.com

Web Site: http://www.wuxipharmatech.com/
COPYRIGHT 2008 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 21, 2008
Words:521
Previous Article:Oil Refineries' Board Approves an Outline For Potential Acquisition of Balance of Carmel Olefins.
Next Article:WestLB Mellon Asset Management Selects BNY Mellon Asset Servicing to Provide Luxembourg Fund Services For its Longitude SICAV.


Related Articles
WuXi PharmaTech (NYSE: WX) Holds Its First Life Science and Chemistry Awards Ceremony in Beijing.
WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO.
WuXi PharmaTech (NYSE: WX) Hosts Its First Supplier Conference in Shanghai.
Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists.
WuXi PharmaTech (NYSE: WX) Endows a New Faculty Position at Tongji University.
WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca.
WuXi AppTec VP and GM Invited to Join the AAMI Standards Board.
Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry.
WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development.
Professor K. C. Nicolaou Speaks at WuXi AppTec.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters